0.90

7.21% 0.0605

After Hours: .89 -0.01 -1.11%

Mira Pharmaceuticals Inc (MIRA)

Overview News Price History Discussions Forecast

Mira Pharmaceuticals Inc stock is traded at $0.90, with a volume of 94,205. It is up +7.21% in the last 24 hours and up +16.08% over the past month. Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

Previous Close:

$0.8395

Open:

$0.8602

24h Volume:

94,205

Relative Volume:

0.17

Market Cap:

$37.82M

Revenue:

Net Income/Loss:

$-31.37M

P/E Ratio:

-0.6259

EPS:

-1.438

Net Cash Flow:

$-4.23M

1W Performance:

+8.13%

1M Performance:

+16.08%

6M Performance:

-19.64%

1Y Performance:

-30.77%

1-Day Range:

$0.85

$0.90

1-Week Range:

$0.7984

$0.94

52-Week Range:

$0.60

$2.45

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Name

Mira Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - General (20)

Phone

813-369-5150

Address

1200 BRICKELL AVENUE, MIAMI

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

MIRA's Discussions on Twitter

Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRA Mira Pharmaceuticals Inc	0.90	37.82M	0	-31.37M	-4.23M	-1.438
LLY Lilly Eli Co	1,183.46	1.05T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	271.22	653.61B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	264.34	467.12B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	148.78	367.07B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	145.46	276.48B	54.66B	13.58B	16.05B	7.0171

Mira Pharmaceuticals Inc Stock (MIRA) Latest News

Sep 25, 2026

Millions of Cancer Patients and Survivors Live With Persistent Nerve Pain. MIRA Is Advancing Ketamir-2 Into Its First Patient Study - Barchart.com

Sep 25, 2026

What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks? - Kalkine Media

Sep 25, 2026

Sep 18, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Sep 18, 2026

Sep 17, 2026

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review - Investing.com

Sep 17, 2026

MIRA Advances Ketamir-2 Phase 2a Trial Protocol for CIPN; Market Reflects Cautious Outlook - GuruFocus

Sep 17, 2026

MIRA advances Ketamir-2 Phase 2a neuropathy program - TipRanks

Sep 17, 2026

MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com India

Sep 17, 2026

Maxim Group Initiates MIRA Pharmaceuticals(MIRA.US) With Buy Rating, Announces Target Price $3.5 - Moomoo

Sep 17, 2026

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review - Yahoo Finance

Sep 17, 2026

Sep 16, 2026

63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - Stock Titan

Sep 16, 2026

Sep 08, 2026

Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com

Sep 08, 2026

Sep 07, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire

Sep 07, 2026

Sep 02, 2026

This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com

Sep 02, 2026

Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News

Sep 02, 2026

Sep 01, 2026

Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga

Sep 01, 2026

MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa

Sep 01, 2026

MIRA-55 toxicology results advance non-opioid pain program - TipRanks

Sep 01, 2026

MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com

Sep 01, 2026

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire

Sep 01, 2026

Aug 23, 2026

MIRA (MIRA) Results Breakdown: The Company Lists Its Latest Available Figures for This Review; Shares Move 4.66% HigherEPS Estimate Trend - dars.gov.et

Aug 23, 2026

Aug 21, 2026

MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionSocial Sentiment - dars.gov.et

Aug 21, 2026

Aug 18, 2026

MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn

Aug 18, 2026

Aug 17, 2026

MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn

Aug 17, 2026

Aug 12, 2026

MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - marketbeat.com

Aug 12, 2026

Aug 11, 2026

MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelEnding Diagonal - careplusvn.com

Aug 11, 2026

Aug 10, 2026

MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineMargin Expansion Trends - careplusvn.com

Aug 10, 2026

Aug 09, 2026